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INTRODUCTION
Gold-based drugs have been used for over sixty years for the treatment of rheumatoid arthritis. They are among only a few drugs which have been tested in a double blind study and shown to be effective in inducing remission of the disease (1). In spite of the reported efficacy of the drugs, there is no clear understanding of their mechanism of action. It is also unclear why some individuals experience severe toxicity under the same regimen which gives others positive results. For several years, we have been interested in developing methods to detect goldcontaining metabolites in patient fluids. Based on an in vitro experiment to monitor intestinal uptake of auranofin (triethylphosphinegold(I)tetraacet1thioglucose, AF), we showed that it was a metabolite of the drug and not the drug itself which crosses the intestinal wall (2). More recently, we have developed methods using high performance liquid chromatography, HPLC, interfaced to an inductively coupled plasma-mass spectrometer, ICP-MS, for gold-specific detection to analyze blood and urine samples from patients (3) (4) (5) . These experiments have shown that the drugs themselves do not circulate in patients to any significant extent. Thus, gold effects are due to gold-containing metabolites.
Recently, we have identified one of the gold-containing metabolites found in patient fluids (6), dicyanogold(I), [Au(CN)2]. This compound was found first in urine samples from a patient being treated with myochrysine (sodium gold thiomalate, AuTm) but was subsequently found in both blood and urine samples.from patients being treated with both solganol (gold thioglucose, AuTg) and AF. This represented the first identification of gold-containing metabolites in patient fluids and the first evidence that the three different gold-based drugs have common metabolites. Dicyanogold was found at the highest levels in patients who reported that they smoked, but was also found in reported nonsmokers.
Patients treated with myochrysine show wide variation in the amount of gold found in their red blood cells (RBCs)(7). Graham, et al. (8) HIV culture, reverse transcriptase assays: All work was carried out in the P3 facility of the Laboratory of Clinical Virology. Cells from a logarithmically growing H9 culture were centrifuged at 800 RPM for 10 rain, then counted and resuspended at x 108 cells per mL. 2 mL was added to each of 2 centrifuge tubes and cells were pelleted as above. Cell pellets were resuspended in 0.4-0.5 mL of HIV inoculum and incubated at 37 C for two hours, resuspending the cells gently at 30 min intervals. Cells were then pelleted, then washed, pelleted again, and suspended in 10 mL of fresh medium (2 x 106 cells/mL). 20 ppb dicyanogold(I) was added to one culture. Cultures were placed in 25 cm 2 flasks and incubated at 37 C with a 5% CO= atmosphere. At 3-4 day intervals, cells were counted, assessed for viability, and diluted to 2 x 106 cells per mL. At each time point, mL of growth medium was saved after removing the cells by centrifugation. These medium samples were saved and stored for assays of reverse transcriptase activity (10).
RESULTS AND DISCUSSION
We have used FIA with ICP-MS detection to monitor gold levels in plasma and urine samples from patients treated with gold-based antiarthritis drugs. Most of our work has been with samples from patients on AuTm therapy, since that is the principal gold drug administered at the Arthritis Clinic at the University of Cincinnati. Gold levels in AuTm patients show a steady increase from the beginning of therapy until reaching a steady state level at about 30 days (following weekly injections). Gold levels in plasma samples are typically around 2 ppm, once the steady state level has been reached. Although there seems to be relatively little variability among patients in plasma gold levels, gold levels in the RBC lysates are extremely variable. In two patients at the same stage of treatment with the same treatment regimen, one has gold levels in the RBC lysates that are 15% of the level in the plasma, while another has levels essentially identical to those in the plasma. These differences may not be directly attributable to smoking, since both of these patients report that they are occasional smokers. However, independent verification of smoking frequency may be required to demonstrate a connection.
Red blood cell lysates from patients have been examined by HPLC to determine the intracellular binding sites for the gold. Figure shows a being treated with myochrysine contains high levels of gold. The majority of the gold is bound to high molecular weight materials, a minor constituent has the retention time for hemoglobin.
Another of the proteins has an apparent molecular weight of 300,000 Da. Among the low molecular weight gold species present, there are gold peaks which correspond to dicyanogold(I) and also to a bis(glutathione)gold(I) complex. We tested this possibility by using an irreversible inhibitor of the red blood cell anion channel, 4,4'-diisothiocyanatostilbene-2,2'-sulfonic acid (DIDS) (9). At daily intervals, cell number was determined with a hemocytometer.
ranging from 10 to 100 ppb. After an initial lag, the cells with no added dicyanogold increased with an apparent doubling time of approximately 22 hours. Cells exposed to 10 ppb or 20 ppb dicyanogold(I) doubled at control rates. The cells grown in 50 ppb, showed a more significant lag before an increase in number was observed. However, by the third day of culture, doubling times approached control levels. The cells exposed to 100 ppb dicyanogold began to grow after several days, but did not grow at control rates during this experiment. In later experiments, cells were maintained in 100 ppb for longer periods and after an initial lag doubled at control rates. We also examined the effects of dicyanogold(I) on H9 cells using the criterion of cell viability rather than growth rate. Cells were again exposed to varying concentrations of dicyanogold(I) and at regular intervals cells in each culture were tested for cell viability using the trypan blue dye exclusion method. Figure 4 shows that the initial effects on cell viability clearly correlate with the Since H9 cells can tolerate relatively high levels of dicyanogold(I), we were interested in determining the extent of uptake of gold.by H9 cells exposed to this compound. A series of cultures was set up with 8.7 x 106 cells per mL. These cultures were incubated with varying concentrations of dicyanogold(I) for one hour at 37C. At the end of the incubation, cells were removed by centrifugation. Cell pellets were washed in PBS, then cells were iysed as was done with the red blood cells. Cell lysates were assayed for gold amounts by FIA with the ICP-MS. Figure 5 shows that the cells exposed to dicyanogold accumulated gold to levels dependent on the external concentration. In all cases, the amount of gold found within the cell lysates was at least 70 fold greater than the concentration in the corresponding incubation medium. This shows that the H9 cells concentrate gold when incubated with dicyanogold. This is a critical result if the cells are to achieve gold concentrations necessary to/nhibit HIV.
H9 cells were also used to further investigate the mechanism of uptake of gold from dicyanogold(I) incubation. It has been proposed that gold compounds may enter cells via a "sulfhydryl shuttle" (13). In this model, gold complexes undergo ligand exchange to bind to sulfhydryl groups in or on the cell membrane. In a series of reactions, the gold passes through the membrane where it is then released into the cytosol. The sulfhydryl shuttle is expected to be inhibited by compounds which block surface sulfhydryl groups, such as N-ethylmaleimide (NEM).
To test whether blocking surface sulfhydryl groups interferes with gold uptake in H9 cells, the cells were incubated with mM NEM at 37 C for 30 min. The NEM was then removed by centrifugation of the cells. The cells were rinsed in complete medium, centrifuged again, then resuspended in complete medium and exposed to varying concentrations of dicyanogold(I) as above. As shown in Figure 5 , NEM significantly blocks the uptake of gold in this experiment. This result is consistent with the suifhydryl shuttle mechanism of uptake. 
CONCLUSIONS
We have used FIA with ICP-MS detection to monitor gold levels in patients being treated with gold-based antiarthritis drugs. Our studies show that gold levels in patient blood samples generally are in the range of 0.5-3 ppm. Although patients on myochrysine may have comparable levels of gold in their blood plasma, they vary in the amount of gold in their red blood cells. This observation is consistent with previous findings (7, 8) . By chromatographic analysis of plasma samples from these patients, we have shown that dicyanogold is found in the blood independent of the original drug administered. Graham, et al. (8) had predicted with dicyanogold was a likely metabolite, especially in smokers. While we see higher levels of dicyanogold in smokers, we can also detect it in non-smoking patients.
Analysis of red blood cell lysates from patients shows that the majority of the gold is bound in high molecular weight form. Although some of the gold appears to be bound to hemoglobin, the gold is also found in a higher molecular weight fraction. Among the low molecular weight gold species present in the red blood cell Iysates are dicyanogold(I), and bis(glutathione)gold(I) complexes.
In vitro studies show that dicyanogold incubation results in rapid uptake of gold by red blood cells. This uptake is not affected by the inhibitor of the anion channel, DIDS, which shows that dicyanogold does not enter the cells through the anion channel. Excess cyanide does inhibit uptake of gold in dicyanogold incubations, which indicates that uptake involves the loss of a cyanide moiety.
Studies on the CD4* cell line, H9, confirm that incubation of cells with dicyanogoid leads to significant uptake of gold. The uptake of gold is concentration dependent, and cell lysates have gold levels at least 70 fold higher than the external medium. This concentration of gold by cells is significantly inhibited by pretreatment of the cells with NEM. The fact that blocking surface sulfhydryIs affects gold uptake is consistent with the proposed sulfhydryI shuttle mechanism (13). Further studies are clearly warranted to determine whether dicyanogold(I), either alone or in combination with other agents, will provide a useful therapeutic for AIDS.
